Hepatitis C in Children and Adolescents: State of the Art

Hepatitis C virus (HCV) infection is an important cause of chronic liver disease in children and adolescents, despite its often asymptomatic and indolent course. In infants and children, infection is mainly acquired through vertical transmission, while horizontal transmission becomes increasingly relevant during adolescence. The introduction of direct-acting antivirals (DAAs) has revolutionised HCV management, providing highly effective and well-tolerated treatments. Current international guidelines recommend treatment for all children and adolescents aged ≥ 3 years with chronic HCV infection, preferably with pangenotypic, ribavirin-free regimens. Glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are the main first-line options. Sofosbuvir plus daclatasvir represents an additional World Health Organization-recommended option, particularly in resource-limited settings. Despite these advances, early diagnosis, treatment adherence, and equitable access to DAAs remain essential to achieve HCV elimination in children.

Authors

Institutions

Publication Details

Journal
Pediatric Reports
Published
2026-11-19
DOI
https://doi.org/10.3390/pediatric18060153
Primary Topic
Hepatitis C virus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hepatitis C in Children and Adolescents: State of the Art

Giuseppe Indolfi, Simona Carrera, Chiara Rubino, Federica Attaianese et al.
Pediatric Reports
Hepatitis C virus research
article

Hepatitis C in Children and Adolescents: State of the Art

Giuseppe Indolfi, Simona Carrera, Chiara Rubino, Federica Attaianese, Elisa Bartolini
article en

Abstract

Hepatitis C virus (HCV) infection is an important cause of chronic liver disease in children and adolescents, despite its often asymptomatic and indolent course. In infants and children, infection is mainly acquired through vertical transmission, while horizontal transmission becomes increasingly relevant during adolescence. The introduction of direct-acting antivirals (DAAs) has revolutionised HCV management, providing highly effective and well-tolerated treatments. Current international guidelines recommend treatment for all children and adolescents aged ≥ 3 years with chronic HCV infection, preferably with pangenotypic, ribavirin-free regimens. Glecaprevir/pibrentasvir and sofosbuvir/velpatasvir are the main first-line options. Sofosbuvir plus daclatasvir represents an additional World Health Organization-recommended option, particularly in resource-limited settings. Despite these advances, early diagnosis, treatment adherence, and equitable access to DAAs remain essential to achieve HCV elimination in children.

Pediatric ReportsVol. 18(6)
Meyer Children's Hospital (IT), University of Florence (IT)
Hepatitis C virus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon